Medcenter Nova Clinic Ltd.

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Type 2 diabetes5 trials
• Graves' disease3 trials
• Obesity3 trials
• Atrial fibrillation2 trials
• Chronic kidney disease1 trial
• COPD1 trial
• Heart failure1 trial
• Sjögren's disease1 trial
• Stroke1 trial

Phase

• Phase 310 trials
• Phase 24 trials

Status

• Active, not recruiting5 trials
• Recruiting5 trials
• Completed4 trials

Lead sponsor

• AstraZeneca3 trials
• Novo Nordisk A/S3 trials
• Immunovant Sciences GmbH2 trials
• Pfizer2 trials
• Acesion Pharma1 trial
• and 3 more

Running trials

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

  NCT07662135· Phase 3· AstraZeneca· Source

• Recruiting

  A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease

  2025-524001-33-00· Phase 2· Immunovant Sciences GmbH· Source

• Recruiting

  A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.

  NCT07596849· Phase 3· argenx· Source

• Active, not recruiting

  AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

  NCT07400107· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

  NCT07400653· Phase 3· Pfizer· Source

• Active, not recruiting

  Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

  NCT07311850· Phase 3· Pfizer· Source

• Recruiting

  Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation

  NCT07267949· Phase 2· Acesion Pharma· Source

• Active, not recruiting

  Trial of Sibeprenlimab in the Treatment of Sjögren’s Disease

  2024-516295-14-00· Phase 2· Otsuka Pharmaceutical Development & Commercialization Inc.· Source

• Recruiting

  A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

  NCT07018323· Phase 2· Immunovant Sciences GmbH· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Graves' disease2 recruiting
• Atrial fibrillation1 recruiting
• Chronic kidney disease1 recruiting
• Heart failure1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes

  NCT06340854· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD

  NCT06075095· Phase 3· AstraZeneca· Source

• Completed

  A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06065540· Phase 3· Novo Nordisk A/S· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source